Pasithea Therapeutics
Opens Second Ketamine Therapy Clinic in the United
Kingdom
-- Expanding Pasithea Clinics footprint in London
--
Miami Beach, FL -- December 21st, 2021 --
InvestorsHub NewsWire -- Pasithea Therapeutics Corp. (Nasdaq:
KTTA) ("Pasithea" or the "Company"), a novel
biotechnology company focused on the research and discovery of new
and effective treatments for psychiatric and neurological
disorders, today announced that its wholly owned subsidiary,
Pasithea Clinics, has opened its second London clinic in
Marylebone offering intravenous ("IV") ketamine
therapy to patients suffering from treatment-resistant mental
health issues. The Company opened its first U.K. clinic in
Knightsbridge in October 2021.
"Through our second London clinic, we are pleased to increase
access to this important therapy for patients in the U.K. with
treatment-resistant mental health disorders," stated Dr. Tiago Reis
Marques, CEO of Pasithea Therapeutics. "More than ever, new
treatment therapies are urgently needed for these patients and by
broadening our coverage, we can work to close the treatment
gap."
"Two decades of research supports the efficacy of ketamine in
improving symptoms experienced in some mental health disorders.
With the opening of our Marylebone
location, we are expanding our footprint in the U.K. and will
continue to work toward bringing this treatment option to patients
nationwide," said Dr. Yassine
Bendiabdallah, Managing Director of Pasithea Clinics in the
UK.
Ketamine is a U.S. Food and Drug Administration ("FDA")
approved drug introduced to the medical community as an anesthetic
more than 50 years ago. It has recently been repurposed for the
treatment of psychiatric disorders using significantly lower doses
than in anesthesia and is gaining ground as a promising treatment
for mental health disorders. In certain psychiatric conditions,
such as treatment-resistant depression ("TRD") and post-traumatic
stress disorder ("PTSD"), it has shown remarkable efficacy and a
rapid and sustained effect.
Major Depression is the leading cause of long-term disability
worldwide, according to the World Health Organization, with
existing treatments having limited success rates, numerous side
effects and onset of action delayed by several weeks. Studies have
shown that up to 70% of those who
receive IV ketamine treatment can eventually show a clinical
response. While the number of treatments suggested is done on a
case-by-case basis, a typical treatment plan consists of up to six
infusions in the interval of two to three weeks.
About Pasithea
Therapeutics Corp.
Pasithea Therapeutics
Corporation is a U.S. biotechnology company focused on the research
and discovery of new and effective treatments for psychiatric and
neurological disorders. With an experienced team of experts in the
fields of neuroscience and psychopharmacology, Pasithea is
developing new molecular entities for the treatment of psychiatric
and neurological disorders. Pasithea is also focused on addressing
the needs of patients currently suffering with mental illness by
providing access to IV ketamine infusions both in clinics and
in-home settings.
Forward
Looking Statements
This press release contains statements that constitute
"forward-looking statements." Forward-looking statements are
subject to numerous conditions, many of which are beyond the
control of the Company. While the Company believes these
forward-looking statements are reasonable, undue reliance should
not be placed on any such forward-looking statements, which are
based on information available to the Company on the date of this
release. These forward-looking statements are based upon current
estimates and assumptions and are subject to various risks and
uncertainties, including, without limitation, those set forth in
the Company's filings with the SEC. Thus, actual results could be
materially different. The Company undertakes no obligation to
update these statements whether as a result of new information,
future events or otherwise, after the date of this release, except
as required by law.
Pasithea Therapeutics Corp. Company
Contact
Dr. Tiago Reis
Marques
Chief Executive
Officer
E:
tiago@pasithea.com
Pasithea Therapeutics Corp. Investor
Relations
Lisa M.
Wilson
In-Site
Communications, Inc.
T:
212-452-2793
E:
lwilson@insitecony.com